NRX Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable
NRX Pharmaceuticals, Inc. (NRXP) reported Increase (Decrease) in Accounts Receivable of $98.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $50.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $48.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$36.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$12.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$48.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2021 was -$831.00K, a 200.00% decline from fiscal 2020.
- NRX Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2020 was $831.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $98.00K 10-Q · filed 2026-08-14 | $62.00K derived: sum of 3 quarters · filed 2026-08-14 | $50.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $48.00K 10-Q · filed 2026-05-15 | $12.00K derived: sum of 2 quarters · filed 2026-05-15 | $0.00 derived: sum of 3 quarters · filed 2026-05-15 | $0.00 derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | -$36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$48.00K derived: sum of 2 quarters · filed 2026-03-23 | -$48.00K derived: sum of 3 quarters · filed 2026-08-14 | -$48.00K 10-K · filed 2026-03-23 | ||
| 2025-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$12.00K derived: sum of 2 quarters · filed 2026-08-14 | -$12.00K 10-Q · filed 2025-11-14 | -$12.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | -$831.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | -$831.00K 10-Q · filed 2022-11-14 | -$831.39K 10-Q · filed 2021-11-15 | -$1.25M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$831.00K 10-Q · filed 2022-08-15 | -$831.39K 10-Q · filed 2021-08-16 | -$1.25M derived: sum of 3 quarters · filed 2022-08-15 | -$314.22K derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$831.00K 10-Q · filed 2022-05-16 | -$1.25M derived: sum of 2 quarters · filed 2022-05-16 | -$314.22K derived: sum of 3 quarters · filed 2022-08-12 | |||
| 2020-12-31 | -$423.09K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $516.78K derived: sum of 2 quarters · filed 2022-08-12 | $831.00K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $939.87K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $1.25M 10-Q/A · filed 2022-08-12 | ||||
| 2020-06-30 | $314.22K 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |